Global Pharmacovigilance Market Strategic Research Report

The global pharmacovigilance market occupies a critical position within the life sciences regulatory ecosystem, encompassing the scientific activities and processes organizations deploy to detect, assess, understand, and prevent adverse effects or any other drug-related problems. Valued at approximately USD 9.8 billion in 2024, the market has matured from a predominantly paper-based compliance function into a technology-intensive discipline spanning signal detection, risk management, and post-marketing surveillance across the full pharmaceutical product lifecycle. Regulatory agencies including the U.S. Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency have progressively tightened reporting obligations, transforming pharmacovigilance from a regulatory cost center into a strategic capability that directly influences drug approval timelines, product labeling, and commercial viability.

Three interconnected forces are accelerating market expansion through the forecast period. First, the unprecedented volume of new molecular entities entering post-marketing surveillance simultaneously — including the wave of biologics, biosimilars, and cell and gene therapies approved since 2020 — is multiplying case processing workloads far beyond what legacy systems can absorb at acceptable cost. Second, the mandated transition toward electronic Individual Case Safety Report submissions under ICH E2B(R3) and EU XEVMPD standards is compelling pharmaceutical companies of all sizes to modernize their data architectures, creating durable demand for both software platforms and outsourced services. Third, the proliferation of real-world data sources — electronic health records, wearable devices, patient registries, and social media — is generating structured demand for AI-assisted signal detection tools capable of processing unstructured text at scale. The principal restraint constraining faster adoption is the acute shortage of qualified pharmacovigilance professionals worldwide; the specialized intersection of clinical, regulatory, and data science competencies required creates recruitment bottlenecks that inflate labor costs and extend implementation timelines for in-house programs.

This report provides a comprehensive quantitative and qualitative assessment of the global pharmacovigilance market across the 2025–2032 forecast period, with 2024 as the base year. Coverage spans market segmentation by service type, deployment model, end-user, and therapeutic area, alongside regional and country-level forecasts, competitive benchmarking of ten major participants, and an evaluation of emerging trends in AI-driven automation and decentralized surveillance. The report is intended for corporate strategy teams evaluating build-versus-buy decisions, investment analysts assessing outsourcing platform consolidation, M&A advisors benchmarking contract research organization valuations, and procurement managers negotiating pharmacovigilance service agreements.